Chinese vaccine enterprises shift from product export to capability transfer

China's human vaccine exports rose 53.51% year-on-year in 2025 to approximately $345 million, but the more consequential shift is structural: Chinese enterprises are now embedding manufacturing, regulatory, and R&D capabilities directly into partner countries rather than simply shipping product.